Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Self-citationLenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
“Diarrhea 9 (15) 4 (6) 1 (2) 1 (2) 1 (2)”
Influentialvan de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 888
“plasma cells, a risk-stratification model was developed (20).”
BackgroundSelf-citationThe genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Randomized trial of lenalidomide versus observation in smoldering multiple myeloma
Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A. M., Buadi, F. K., O’Brien, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01740 · Cited by 908
Self-citationKyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 855
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“In some patients, an intermediate asymptomatic but more advanced premalignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically.(20) SMM progresses to multiple myeloma at a rate of approximately 10% per year over the first 5 years following diagnosis, 3% per year over the next 5 years…”
BackgroundSelf-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.(18) Patients with the highest risk of”
BackgroundSelf-citationDispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815
“The extent of abnormality of rFLC was independent of SMM risk categories defined by the number of bone marrow plasma cells (BMPC) and size of serum M proteins.(23) A risk model was constructed, incorporating the best breakpoint of rFLC, BMPC ≥ 10%, and serum M protein ≥3 g/dL.”
MethodSelf-citationMultiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.(11) Patients with the highest risk of progression (ultrahigh risk) have now been reclassified as having MM by the new International Myeloma Working Group crite…”
BackgroundSelf-citationMultiple myeloma epidemiology and survival: A unique malignancy
Kazandjian, D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.004 · Cited by 765
A clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709974 · Cited by 647
Self-citationRöllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
“Although SMM has a much higher risk of progression to symptomatic myeloma (10% per year in the first 5 years), many of these patients can be observed for years before any active therapy is required.(26) Given the lack of any demonstrated benefit for initiating therapy for this early disease stage,(27,28) it is importa…”
BackgroundSelf-citationA monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 569
“Bone marrow plasma cells, % (range) 50 (2-95) 50 (1-95) .”
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
Leung, N., Bridoux, F., Hutchison, C. A., Nasr, S. H., Cockwell, P., Fermand, J.-P., Dispenzieri, A., Song, K. W., & Kyle, R. A. (2012) · Blood · doi:10.1182/blood-2012-07-445304 · Cited by 548
Self-citationHillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Riva, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30309-2 · Cited by 516
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Self-citationMikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
“org n from MGUS with a greater burden of plasma cells in the bone marrow (>10%) and a higher annual risk of transformation to MM (10% for the first 5 years with subsequent reduction).(5,6) Hallmark features of MM are highlighted by the acronym CRABdCalcium elevation, Renal insufficiency, Anemia, and Bone diseasedwith…”
BackgroundSelf-citationInterleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
“Smoldering multiple myeloma constitutes an early stage of multiple myeloma as patients develop the disease within one to two years later [176].”
BackgroundMultiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Self-citationDimopoulos, M., Kyle, R., Fermand, J.-P., Rajkumar, S. V., San Miguel, J., Chanan-Khan, A., Ludwig, H., Joshua, D., Mehta, J., Gertz, M., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299529 · Cited by 454
Self-citationDispenzieri, A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D., Benson, J., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2008) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 433
“Serum M protein, median g/L (range) 29 (5-54)”
Self-citationMalard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Hillengass, J., Fechtner, K., Weber, M.-A., Bäuerle, T., Ayyaz, S., Heiss, C., Hielscher, T., Moehler, T. M., Egerer, G., Neben, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5356 · Cited by 381
“lative probability of progression is 73% at 15 years, but there is great interindividual variability.(3) There-”
BackgroundZavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0053-3 · Cited by 374
Self-citationMultiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 355
Self-citationUpdated Diagnostic Criteria and Staging System for Multiple Myeloma
Rajkumar, S. V. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159009 · Cited by 350
Self-citationMonoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
Fermand, J.-P., Bridoux, F., Dispenzieri, A., Jaccard, A., Kyle, R. A., Leung, N., & Merlini, G. (2018) · Blood · doi:10.1182/blood-2018-04-839480 · Cited by 299
“Manifestations associated with monoclonal gammopathies can result from various, sometimes intertwined mechanisms: (1) expansion of clonal malignant cells; (2) secretion of a large amount of MIg, which can cause tumor-mass–related manifestations, including hyperviscosity and LC cast nephropathy; (3) secondary alteratio…”
BackgroundSelf-citationRisk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Dingli, D., Fonder, A. L., Hayman, S. R., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0077-4 · Cited by 303
“(high risk) of bone marrow-plasma cell percentage (BMPC%) > 20%, free light chain ratio (FLCr) > 20, and high-risk cytogenetics [del17p, t(4;14) or”
BackgroundSelf-citationGuidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 306
“The overall risk of progression is 10% per year for the first 5 years but, interestingly, declines in subsequent years (Kyle et al, 2007).”
BackgroundThe multiple myelomas — current concepts in cytogenetic classification and therapy
Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0018-y · Cited by 302
Self-citationPathogenesis beyond the cancer clone(s) in multiple myeloma
Bianchi, G., & Munshi, N. C. (2015) · Blood · doi:10.1182/blood-2014-11-568881 · Cited by 288
“WhereasMGUS progresses to MM and related dyscrasia with an unremitting rate of 1% per year, SMM patients have a 10%-per-year rate of progression within the first 5 years of diagnosis, which then progressively reduces but never disappears, thus prompting more intense monitoring as compared to MGUS.(14) Recently, diagno…”
BackgroundResultInfluentialInternational Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00366-3 · Cited by 291
Self-citationRajkumar, S. V., Landgren, O., & Mateos, M.-V. (2015) · Blood · doi:10.1182/blood-2014-09-568899 · Cited by 269
“SMM is distinguished from MGUS primarily for clinical reasons, because the risk of progression to malignancy in the first 5 years after diagnosis is different: 10%per year in SMMvs 1%per year inMGUS.(1) SMM is biologically heterogeneous; it is a clinically defined entity comprisinga subset of patientswithbiological pr…”
BackgroundMethodResultInfluentialSelf-citationWalker, B. A., Wardell, C. P., Melchor, L., Brioli, A., Johnson, D. C., Kaiser, M. F., Mirabella, F., Lopez-Corral, L., Humphray, S., Murray, L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.199 · Cited by 283
Rajkumar, S. V. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.63 · Cited by 289
“or a more advanced indeterminate stage termed smoldering multiple myeloma (SMM)”
BackgroundSelf-citationWhy not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
“[59] Several years of research has focused on the role of IL-1β and IL-6 in the pathogenesis of multiple myeloma.”
BackgroundMultiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277
Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y.-T., Prabhala, R. H., Ritz, J., Neuberg, D., Anderson, K. C., Carrasco, D. R., & Dranoff, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711293105 · Cited by 256
“Peripheral blood CD8 cells from MM patients with sMICA also evidenced diminished NKG2D, in contrast to the normal levels in MGUS subjects and the modest decrease in the SMM patient (Fig.”
BackgroundLust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.114 · Cited by 246
“Age (y) 60 (38-79) Sex Male 25 (53) Female 22 (47) Diagnosis SMM 34 (72) IMM (lytic disease) 13 (28) Ig subtype IgG 40 (85) IgA 7 (15) BMPCs (%) 27 (4-60) BMPCs 20% 38 (81) IL-1 level (IL-6 FI) ≥1b 40 (85) PCLI (%) 0.”
Self-citationSerum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
Larsen, J. T., Kumar, S. K., Dispenzieri, A., Kyle, R. A., Katzmann, J. A., & Rajkumar, S. V. (2013) · Leukemia · doi:10.1038/leu.2012.296 · Cited by 239
Self-citationEvolutionary biology of high-risk multiple myeloma
Pawlyn, C., & Morgan, G. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.63 · Cited by 238
Rajkumar, S. V., Gupta, V, Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., Ketterling, R. P., Lust, J. A., Kyle, R. A., & Kumar, S. K. (2013) · Leukemia · doi:10.1038/leu.2013.86 · Cited by 239
Self-citationCuring myeloma at last: defining criteria and providing the evidence
Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G. J., & Crowley, J. (2014) · Blood · doi:10.1182/blood-2014-07-552059 · Cited by 235
Neben, K., Jauch, A., Hielscher, T., Hillengass, J., Lehners, N., Seckinger, A., Granzow, M., Raab, M. S., Ho, A. D., Goldschmidt, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4923 · Cited by 233
“Here, we address five main questions: (1) What is the frequency and pattern of chromosomal aberrations as assessed by iFISH in patients with SMM? (2) Do these aberrations confer a prognostic significance? (3) Do different chromosomal aberration patterns predict for a specific mode of progression (eg, bone disease)? (4…”
BackgroundMultiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 209
“In some patients, an intermediate asymptomatic but more advanced premalignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically.(19) SMM progresses to multiple myeloma at a rate of”
BackgroundSelf-citationClinically relevant end points and new drug approvals for myeloma
Anderson, K. C., Kyle, R. A., Rajkumar, S. V., Stewart, A. K., Weber, D., Richardson, P., & Myeloma, O. B. O. T. A. /. P. O. C. E. I. M. (2008) · Leukemia · doi:10.1038/sj.leu.2405016 · Cited by 225
Self-citationCalcinotto, A., Brevi, A., Chesi, M., Ferrarese, R., Garcia Perez, L., Grioni, M., Kumar, S., Garbitt, V. M., Sharik, M. E., Henderson, K. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07305-8 · Cited by 223
Self-citationImmunotherapy of multiple myeloma
Minnie, S. A., & Hill, G. R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129205 · Cited by 210
“Whole-exome sequencing of paired patient samples collected at diagnosis of MGUS/ SMM and again at MM found that most somatic mutations preceded diagnosis of clinical MM (16, 17), suggesting that although genetic mutations are necessary for tumorigenesis, they are not sufficient for transformation of myeloma.”
BackgroundInfluentialMultiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 208
Self-citationKorde, N., Kristinsson, S. Y., & Landgren, O. (2011) · Blood · doi:10.1182/blood-2011-01-270140 · Cited by 199
Multiple myeloma in the marrow: pathogenesis and treatments
Fairfield, H., Falank, C., Avery, L., & Reagan, M. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13038 · Cited by 183
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30124-3 · Cited by 193
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Harousseau, J.-L., & Moreau, P. (2009) · New England Journal of Medicine · doi:10.1056/nejmct0805626 · Cited by 186
Dhodapkar, M. V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J. D., Hoering, A., Crowley, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515239 · Cited by 192
Plasma Cell Neoplasms: A Morphologic, Cytogenetic and Immunophenotypic Approach
(2016) · Springer eBooks · doi:10.1007/978-3-319-10918-3 · Cited by 194
Musto, P., Petrucci, M. T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzoni, V., Andriani, A., D'Arena, G., Balleari, E., Pietrantuono, G., et al. (2008) · Cancer · doi:10.1002/cncr.23783 · Cited by 185
Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00437 · Cited by 187
Diagnosis of Smoldering Multiple Myeloma
Rajkumar, S. V., Larson, D., & Kyle, R. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1106428 · Cited by 176
Self-citationBianchi, G., Kyle, R. A., Larson, D. R., Witzig, T. E., Kumar, S., Dispenzieri, A., Morice, W. G., & Rajkumar, S. V. (2013) · Leukemia · doi:10.1038/leu.2012.237 · Cited by 181
Self-citationMGUS to myeloma: a mysterious gammopathy of underexplored significance
Dhodapkar, M. V. (2016) · Blood · doi:10.1182/blood-2016-09-692954 · Cited by 171
“Nonetheless, these criteria have served the field well to harmonize clinical research, and they identify cohorts with distinct risks of progression to myeloma requiring therapy (1% per year for MGUS and 10% per year for AMM).(7,8) Measures of tumor bulk (level of M spike, free light chains), nature of IgH type (IgG vs…”
BackgroundMorice, W. G., Chen, D., Kurtin, P. J., Hanson, C. A., & McPhail, E. D. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.34 · Cited by 167
“In a significant subset of cases, the plasma cells were the predominant cell type recognized by morphology andsor immunohistochemistry; the latter because of the strong immunoreactivity of the plasma cells for CD138 immunoreactivity compared with the weak immunoreactivity of the B-lymphocytes for CD20”
BackgroundSelf-citationMyeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 160
“SMM carries a much higher risk of progression to malignancy (approximately 10% per year) than MGUS (approximately 1% per year) [12,13].”
BackgroundSelf-citationKastritis, E., Terpos, E., Moulopoulos, L. A., Spyropoulou‐Vlachou, M., Kanellias, N., Eleftherakis-Papaiakovou, E., Gkotzamanidou, M. A., Migkou, M., Gavriatopoulou, M., Ρούσσου, Μ., et al. (2012) · Leukemia · doi:10.1038/leu.2012.309 · Cited by 174
Multiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2013) · American Journal of Hematology · doi:10.1002/ajh.23390 · Cited by 159
Self-citationDissecting racial disparities in multiple myeloma
Marinac, C. R., Ghobrial, I. M., Birmann, B. M., Soiffer, J. L., & Rebbeck, T. R. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0284-7 · Cited by 169
Treatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2009.n.056 · Cited by 151
Self-citationMultiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152
Self-citationLópez-Corral, L., Gutiérrez, N. C., Vidriales, M. B., Mateos, M. V., Rasillo, A., García-Sanz, R., Paiva, B., & San Miguel, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1066 · Cited by 149
“To avoid misclassification or overlapping entities, we decided to focus on MGUS patients with more than 1 year of stable follow-up, high-risk SMM and symptomatic MM using well-established criteria (4, 6, 19).”
BackgroundMethodInfluentialSiveen, K. S., Mustafa, N. B., Li, F., Kannaiyan, R., Ahn, K. S., Kumar, A. P., Chng, W. J., & Sethi, G. (2013) · Oncotarget · doi:10.18632/oncotarget.1596 · Cited by 156
“Generally, MM is preceded by two premalignant conditions namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma (SMM) [3, 4].”
BackgroundPrognostic and predictive biomarker developments in multiple myeloma
Wallington-Beddoe, C. T., & Mynott, R. L. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01162-7 · Cited by 172
“MM encompasses a spectrum of clinical variants ranging from benign monoclonal gammopathy of uncertain significance (MGUS) and smouldering/indolent MM (SMM) to more aggressive, disseminated forms of MM and plasma cell leukaemia.”
MethodInfluentialRoadmap to cure multiple myeloma
Rodríguez‐Otero, P., Paiva, B., & Miguel, J. F. S. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102284 · Cited by 160
“It is well established that all MM patients are preceded by a monoclonal gammopathy of undetermined significance (MGUS), and that only a small fraction of MGUS (1% per year) evolve into active MM [1,2].”
BackgroundBlocking interleukin-1β in acute and chronic autoinflammatory diseases
Dinarello, C. A. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02313.x · Cited by 164
“Smoldering myeloma presents a challenge to medicine as the population ages [89].”
BackgroundProgression in smoldering Waldenström macroglobulinemia: long-term results
Kyle, R. A., Benson, J. T., Larson, D. R., Therneau, T. M., Dispenzieri, A. A., Kumar, S. K., Melton, L. J., & Rajkumar, S. V. (2012) · Blood · doi:10.1182/blood-2011-10-384768 · Cited by 149
Self-citationMultiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144
Self-citationZamagni, E., Nanni, C., Gay, F., Pezzi, A., Patriarca, F. F., Bellò, M., Rambaldi, I., Tacchetti, P., Hillengaß, J., Gamberi, B., et al. (2015) · Leukemia · doi:10.1038/leu.2015.291 · Cited by 146
Rögnvaldsson, S., Löve, Þ. J., Þorsteinsdóttir, S., Reed, E. R., Óskarsson, J. Þ., Pétursdóttir, Í., Sigurðardóttir, G. Á., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00480-w · Cited by 147
Laubach, J., Richardson, P., & Anderson, K. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070209-175325 · Cited by 139
Dutta, A. K., Fink, J. L., Grady, J. P., Morgan, G. J., Mullighan, C. G., To, L. B., Hewett, D. R., & Zannettino, A. C. W. (2019) · Leukemia · doi:10.1038/s41375-018-0206-x · Cited by 136
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma
Jones, C. I., Zabolotskaya, M. V., King, A. J., Stewart, H. J. S., Horne, G. A., Chevassut, T. J., & Newbury, S. F. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.525 · Cited by 136
“A variant of MGUS is asymptomatic or smouldering plasma cell myeloma where the diagnostic criteria for multiple myeloma are met but there is no related organ or tissue impairment (Kyle et al, 2007).”
BackgroundSanoja-Flores, L., Flores-Montero, J. A., Garcés, J., Paiva, B., Puig, N., García‐Mateo, A., García-Sánchez, O., Corral-Mateos, A., Burgos, L., Blanco, E., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0153-9 · Cited by 144
How I treat multiple myeloma in younger patients
Stewart, A. K., Richardson, P. G., & San-Miguel, J. F. (2009) · Blood · doi:10.1182/blood-2009-07-204651 · Cited by 133
Kastritis, E., Moulopoulos, L. A., Terpos, E., Koutoulidis, V., & Dimopoulos, M. A. (2014) · Leukemia · doi:10.1038/leu.2014.230 · Cited by 136
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine
Dutta, A. K., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Lightbody, E. D., Getz, G. A., & Ghobrial, I. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00593-y · Cited by 142
Oben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., Yellapantula, V., Derkach, A., Geerdens, E., Diamond, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22140-0 · Cited by 129
“Analysis of SBS signatures was performed following three main steps: (1) de novo extraction, (2) assignment, and (3) fitting32.”
MethodRajkumar, S. V., Kyle, R. A., & Buadi, F. K. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0520 · Cited by 142
“© 2010 Mayo Foundation for Medical Education and Research Monoclonal gammopathy of undetermined sig-nificance (MGUS) is a premalignant plasma cell disorder present in more than 3% of the general population aged 50 years and older.1,2 MGUS is important to clinicians because it is associated with a 1% per year risk of p…”
BackgroundMethodInfluentialSelf-citationMcKenna, R. W., & Kroft, S. H. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7216-0040-6.00025-3 · Cited by 125
Merz, M., Hielscher, T., Wagner, B., Sauer, S., Shah, S., Raab, M., Jauch, A. T., Neben, K., Hose, D., Egerer, G., et al. (2014) · Leukemia · doi:10.1038/leu.2014.75 · Cited by 125
Panaroni, C., Fulzele, K. S., Mori, T., Siu, K. T., Onyewadume, C., Maebius, A., & Raje, N. S. (2021) · Blood · doi:10.1182/blood.2021013832 · Cited by 129
Levine, A. J., Jenkins, N. A., & Copeland, N. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.009 · Cited by 121
Daratumumab or active monitoring for high-risk smoldering multiple myeloma
Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409029 · Cited by 121
Self-citationThe Genetic Architecture of Multiple Myeloma
Prideaux, S. M., O’Brien, E. C., & Chevassut, T. J. T. (2014) · Advances in Hematology · doi:10.1155/2014/864058 · Cited by 127
“Following MGUS is smouldering multiple myeloma (SMM), another asymptomatic phase distinguished from MGUS by a greater intramedullary tumour cell content of >10% and an average risk of progression to myeloma of 10% per year for the first five years [4].”
BackgroundUpdate on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelínek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 124
“Lenalidomide/ Dexamethasone 20/40 (50) 1/40 (3) 19/40 (48) NCT02036502”
BackgroundDifferential diagnosis of monoclonal gammopathy of undetermined significance
Merlini, G., & Palladini, G. O. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.595.3798563 · Cited by 123
Kristinsson, S. Y., Björkholm, M., Andersson, T., Eloranta, S., Dickman, P. W., Goldin, L. R., Blimark, C. H., Mellqvist, U., Wåhlin, A., Turesson, I., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.010066 · Cited by 129
“Using serially-collected pre-diagnostic serum samples obtained up to almost 10 years prior to the diagnosis of MM, all MM cases were found to have been preceded by MGUS.4 This finding establishes a key role for MGUS in the pathway to MM.”
ResultInfluential
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.